Please login to the form below

Cancer Drugs Fund

This page shows the latest Cancer Drugs Fund news and features for those working in and with pharma, biotech and healthcare.

NICE turns down Keytruda/Inlyta combo for kidney cancer

The agency also says it can’t recommend the regimen for coverage by the Cancer Drugs Fund – which covers the cost of cancer drugs until confirmatory data is available – because “uncertainties ... Opdivo/Yervoy reduced the risk of death by 37% in

Latest news

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

Ibrance. Pfizer received a positive answer from the cost-effectiveness watchdog, with NICE approving its breast cancer drug Ibrance (palbociclib) for use on the Cancer Drugs Fund. ... We are pleased that the company has agreed a managed access agreement
NICE knocks back Roche’s Tecentriq for small cell lung cancer

It also says that Tecentriq shouldn’t be made available for SCLC via the Cancer Drugs Fund – which provides a backup route for patient access to drugs while new evidence is ... SCLC is less common than non-small cell lung cancer (NSCLC) but is a
Pfizer's Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund

Pfizer’s Ibrance has been approved by the National Institute for Health and Care Excellence (NICE) in England through its Cancer Drugs Fund as a second-line treatment for advanced breast ... cancer. Ibrance (palbociclib), in combination with
SMC approves Yescarta and Keytruda, rejects Perjeta

Cancer drugs lead the latest round of recommendations. Gilead’s Yescarta and Merck/MSD’s Keytruda have been accepted by the Scottish Medicines Consortorium for use by NHS Scotland – while ... In August, Keytruda was also made available as a
NICE turns down Roche’s Tecentriq for triple-negative breast cancer

Will also not be included in the Cancer Drugs Fund. Draft guidance from NICE has found that Roche’s Tecentriq shouldn’t be recommended for routine use in patients with ... It also says Tecentriq can’t be considered for inclusion in the Cancer Drugs

More from news
Approximately 53 fully matching, plus 118 partially matching documents found.

Latest Intelligence

30 Women Leaders in UK Healthcare

A very notable victory has just been announced, with Keytruda becoming the first of the groundbreaking immunotherapy drugs to exit the Cancer Drugs Fund and secure NICE approval for first-line ... Current projects include developing antibodies for use as
Uncertainty, austerity and Brexit

Companies have seen repeated attempts by the Government and NHS England to prevent patients from accessing new medicines, from the controversial reforms to the Cancer Drugs Fund to the ‘run rate’
Opening up market access

In this PME market access supplement we look at the direction of travel in France and Germany and there’s an introduction to the UK’s new-look Cancer Drugs Fund.
Stepping up to payer-driven market access

products. In the UK, for instance, NICE now regulates access to the Cancer Drugs Fund, and products will need to meet NICE thresholds in order to be reimbursed.
The price is right?

Health stakeholders should focus not on the cost of drugs but on the value they provide. ... Proposed changes to the Cancer Drugs Fund in England include provision for access at a provisional price that is considered potentially cost-effective.

More from intelligence
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest appointments

New health ministers and re-appointments after reshuffle

Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around ... the uptake of new drugs and med tech, and the
Celgene names general manager for UK and Ireland

This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

How to make the most of online communities

topical healthcare issues including NICE, the Cancer Drugs Fund, biosimilars, the impact of Digital on pharma and the NHS in general.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager (PR): Great Benefits

Experienced medical editor: Competitive salary and bonus scheme

Account Manager: £Competitive Salary

Senior External Communications Lead: £Competitive Salary

Scientific Director: £60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more

Senior Medical Writer, MedComms Agency: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Director, Medical Education: Salary TBC

Account Director: £Competitive Salary

Account Director, Healthcare Communications: Salary TBC

Digital Associate Director - Medcomms: £65000 - £80000 per annum

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Publications director: Competitive salary and bonus scheme

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Account director: Competitive salary and bonus scheme

Subscribe to our email news alerts

PMHub

Add my company

Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Novo Nordisk awakens its ‘Sleeping Beauty’: Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?: Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019: OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...